Skip to content
Original
mp.weixin.qq.com·· 2 days agoScore81

NMPA Approves Bayer's Asundexian to Reduce Stroke Risk After Ischemic Stroke or High-Risk TIA

In brief

China's NMPA has approved, through priority review, the Class 1 innovative drug asundexian tablets (Chinese brand name Shuhuabo), filed by Bayer AG. The drug reduces stroke risk in adults with ischemic stroke or high-risk transient ischemic attack (TIA), excluding cardioembolic stroke patients.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Regulatory#Cardiometabolic#NMPA
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.